🇺🇸 Metoclopramide hydrochloride monohydrate in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 15

Most-reported reactions

1. Diarrhoea — 2 reports (13.33%)
2. Epistaxis — 2 reports (13.33%)
3. Febrile Neutropenia — 2 reports (13.33%)
4. Pyrexia — 2 reports (13.33%)
5. Thrombocytopenia — 2 reports (13.33%)
6. Abdominal Pain — 1 report (6.67%)
7. Antithrombin Iii Decreased — 1 report (6.67%)
8. Atrial Fibrillation — 1 report (6.67%)
9. Colitis — 1 report (6.67%)
10. Hypogammaglobulinaemia — 1 report (6.67%)

Source database →

Frequently asked questions

Is Metoclopramide hydrochloride monohydrate approved in United States?

Metoclopramide hydrochloride monohydrate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Metoclopramide hydrochloride monohydrate in United States?

CM Chungmu Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.